POZEN — Q3 2015 Earnings Presentation
18 slides from POZEN's earnings presentation, Nov 9, 2015
Slide 1: Forward-looking statements
This presentation contains forward-looking statements under applicable securities laws, including, but not limited to, statements related to the anticipated consummation of the business combination transaction among Aralez, POZEN and Tribute and the timing and benefits thereof, the anticipated equit
Slide 2: Topics to Cover
Topics to Cover Key Financial Highlights Aralez Strategic Rationale & Merger Status Fibricor® and YOSPRALA™ Commercialization Strategy Business Development Framework and Focus Short Term Corporate Priorities Question & Answer Session 3
Slide 3: Key Financial Highlights: Revenue
$ millions Q3 2014 Q1 2015 Q2 2015 Q3 2015 Q3 vs. Q2 2015 Q3 vs. Q3 2014 VIMOVO® Royalty $5.5 $4.4 $5.2 $5.8 12% 5% Quarterly TRx (000’s)* 82.5 70.7 99.4 107.0 8% 30% License Fee $2.0 Total Revenue $7.5 $4.4 $5.2 $5.8 12% (23%) POZEN Revenue ROW VIMOVO Royalty rate increases from 6% to 10% in 2016 L
Slide 4: 3Q 2015: Financial Results
3Q 2015: Financial Results Amounts in $M Except Per Share Amounts 3Q 2014 2Q 2015 3Q 2015 Total Revenues $7.5 $5.2 $5.8 Operating Expenses: Research & Development 1.0 2.3 1.8 Commercial 0.0 0.7 2.4 G&A – ongoing 2.6 3.9 5.7 G&A - discrete(1) 0.0 13.6 4.1 Total Selling, General and Administrative 2.6
Slide 5: YTD: Financial Results
YTD: Financial Results Amounts in $M Except Per Share Amounts 9 Months Ended 3Q14 9 Months Ended 3Q15 Total Revenues(1) $22.5 $15.4 Operating Expenses: Research & Development 4.8 5.1 Commercial 0.2 3.5 G&A – ongoing 7.7 12.9 G&A - discrete(2) 0.0 17.3 Total Selling, General & Administrative 7.9 33.7
Slide 6: A Transformational Combination
A Transformational Combination Strong Management with History of Success Diversified, Growing Revenue Base with North American Focus Strong Balance Sheet & Financial Position Irish Domicile Offers Financial & Competitive Advantage $150M at close ($75m equity/$75m convertible note) $200M committed cr
Slide 7: Aralez Status
Aralez Status S-4 has been declared effective by the SEC Preparing for special shareholder meetings of POZEN and Tribute to be held December 10, 2015 and December 9, 2015, respectively; closing shortly thereafter Integration planning underway to ensure a smooth transition Upon close, company will im
Slide 8: Fibricor: Opportunity in Perspective
Fibricor: Opportunity in Perspective Fibricor is a fenofibric acid formulation that is a lipid regulating agent indicated as adjunctive therapy to diet for treatment of severe hypertriglyceridemia (≥ 500 mg/dL), primary hypercholesterolemia or mixed dyslipidemia Product Profile Focused Commercializa
Slide 9: YOSPRALA: Significant Commercial Opportunity Once Approved by the FDA
YOSPRALA: Significant Commercial Opportunity Once Approved by the FDA Market & Product Opportunity An estimated 26 MM* secondary prevention patients in US 70% take aspirin** Over 40% of physicians prescribe or recommend a GI agent when initiating aspirin therapy for secondary prevention patients YOS
Slide 10: YOSPRALA: Proposed Positioning
YOSPRALA: Proposed Positioning YOSPRALA has a coordinated delivery mechanism composed of an enteric-coated aspirin (325 mg or 81mg core), surrounded by immediate-release omeprazole (40 mg) for the secondary prevention of heart attack and stroke for patients at risk for an aspirin-induced ulcer Fixed
Slide 11: YOSPRALA: Market Research Overview
YOSPRALA: Market Research Overview HCPs are Likely to Prescribe YOSPRALA HCPs state reduced pill burden for the patient is attractive1 Combined products ensure patients won’t forget to take second medication1 Automatic GI protection is helpful for patients who have had GI complaints related to Aspir
Slide 12: YOSPRALA: Update
YOSPRALA API Aspirin Manufacturer Status YOSPRALA API primary aspirin manufacturer implementing its action plan to address FDA issues: will be subject to FDA re-inspection Steps also underway to qualify a second supplier of aspirin API Prelaunch Preparations and Tactical Activities Scaling up and bu
Slide 13: Aralez: Strong Projected Revenue Growth
Aralez: Strong Projected Revenue Growth* $75M equity Robust balance sheet and demonstrated access to capital $75M convertible debt 2.5% with 32.5% premium $200M credit facility For future acquisitions * Figures reflect the addition of standalone projections and do not include any synergies or change
Slide 14: Business Development: Framework and Focus
Business Development: Framework and Focus 15 Immediately EBITDA accretive* and near-term revenue generating products Approved products in Cardiovascular and Pain anchor areas Opportunistic approach to other specialty therapeutic areas meeting specified criteria US, Canada and ex-North American geogr
Slide 15: Our Short Term Priorities
Successfully close the Tribute Pharmaceuticals merger in December S-4 has been declared effective by the SEC Hold special shareholder meetings of POZEN and Tribute to be held on December 10, 2015 and December 9, 2015 respectively; closing shortly thereafter Integration planning underway to ensure a
Slide 16: Our Short Term Priorities
Our Short Term Priorities v v v v Successfully close the Tribute Pharmaceuticals merger in December v S-4 has been declared effective by the SEC * Hold special shareholder meetings of POZEN and Tribute to be held on December 10, 2015 and December 9, 2015 respectively; closing shortly thereafter * In
Slide 17: POZEN Corporate Overview 3Q 2015 Financial Results
POZEN Corporate Overview 3Q 2015 Financial Results November 9, 2015
Slide 18: POZEN Corporate Overview 3Q 2015 Financial Results
>> BOLDOUTLOOK POZEN Corporate Overview 3Q 2015 Financial Results November 9, 2015